MedDataX Logo

Optimal End-Tidal (ET) Sevoflurane and Desflurane Concentration for Extubation of Supreme Laryngeal Mask Airway (LMA) in Adults

NCT ID: NCT01083953

Last Updated: 2015-12-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

54 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-11-30

Study Completion Date

2010-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the optimal volatile anaesthetic (sevoflurane and desflurane) to remove a Supreme LMA in adults in which there is minimal airway response.

Null hypothesis: there is no significant difference between the optimal end tidal concentration of sevoflurane and desflurane for Supreme LMA removal.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The manufactures' instructions for removal of the LMA recommend waiting until protective reflexes have returned. However, the appropriate timing for removal remains controversial. A more frequent incidence of airway hyperreactivity and complications has been reported by some studies when the LMA was removed in the awake state versus the anesthetized state. Techniques that reduce the time from LMA removal to the return of protective airway reflexes would minimize the risk of aspiration, contamination, or airway obstruction.

With increasingly common use of Supreme LMA in anaesthetic practice, a safe and suitable depth for removal of the Supreme LMA requires research.

Thus the determination of the optimal end-tidal concentration of commonly used volatile agents ie. Sevoflurane and Desflurane for Supreme LMA removal requires research, both for patient safety and minimising anaesthetic costs in dealing with airway complications.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Airway Complications

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sevoflurane

1 arm will receive sevoflurane at varying concentrations at which extubation is attempted according to the Dixon up and down method

Group Type EXPERIMENTAL

Sevoflurane

Intervention Type DRUG

Comparing the optimal end-tidal concentration sevoflurane and desflurane for LMA extubation

Desflurane

1 arm will receive desflurane at varying end tidal concentration at which extubation will be attempted according to Dixon up and down method

Group Type EXPERIMENTAL

Desflurane

Intervention Type DRUG

Comparing the optimal end-tidal concentration sevoflurane and desflurane for LMA extubation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sevoflurane

Comparing the optimal end-tidal concentration sevoflurane and desflurane for LMA extubation

Intervention Type DRUG

Desflurane

Comparing the optimal end-tidal concentration sevoflurane and desflurane for LMA extubation

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. ASA 1-2 patients
2. Age 18 - 49 years old
3. Elective surgery of short duration ( \< 2 hours ) which require local anaesthetic infiltration

Exclusion Criteria

1. Upper respiratory tract symptoms in the previous 10 days
2. Risk of gastric oesophageal reflux or regurgitation
3. Known or predicted difficult airway
4. Poor dentition with high risk of damage
5. BMI \> 30 kg/m2
6. Refusing to participate
Minimum Eligible Age

18 Years

Maximum Eligible Age

49 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Malaysian Society of Anaesthesiologists

OTHER

Sponsor Role collaborator

University of Malaya

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Cindy Thomas Joseph

doctor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Cindy Thomas Joseph

Role: PRINCIPAL_INVESTIGATOR

Department of Anaesthesiology, UMMC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Malaya Medical Centre

Kuala Lumpur, Kuala Lumpur, Malaysia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Malaysia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

supreme sevo vs des

Identifier Type: -

Identifier Source: org_study_id